CRISPR/Cas9 play­ers cre­ate an IP al­liance as the war with Ed­i­tas heats up

Some of the most promi­nent play­ers in the gene edit­ing field have cre­at­ed an IP-shar­ing al­liance on their CRISPR-Cas9 tech, and Ed­i­tas $ED­IT is con­spic­u­ous­ly ab­sent from the club.

The agree­ment aligns CRISPR Ther­a­peu­tics, In­tel­lia, Cari­bou Bio­sciences and ERS Ge­nomics in what they call a “glob­al cross-con­sent and in­ven­tion man­age­ment agree­ment” for their IP. And the gene-edit­ing club plans to co­or­di­nate their de­fense of tech­nol­o­gy emerg­ing from the labs of Em­manuelle Char­p­en­tier and Berke­ley’s Jen­nifer Doud­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.